OS | PFS | |||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |
Overall cohort | ||||||
IPI >2 | 3.04 | 1.96-3.96 | <.0001 | 2.59 | 1.8-3.62 | <.0001 |
B-symptoms | 1.43 | 1.00-2.04 | .048 | 1.49 | 1.06-2.10 | .024 |
TP53 mutation | 1.59 | 1.06-2.26 | .013 | 1.52 | 1.03-2.17 | .023 |
MUT-p53 subcohort | ||||||
IPI >2 | 2.03 | 1.05-3.93 | .035 | 1.95 | 1.02-3.74 | .042 |
p53 >10% | 2.70 | 1.04-7.04 | .042 | 2.87 | 1.10-7.45 | .031 |
MDM2 >10% | 2.24 | 1.17-4.27 | .015 | 1.96 | 1.03-3.70 | .041 |
LDH, lactate dehydrogenase; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease.
For therapy response, we calculated P values as CR vs other responses. Some clinical features of certain cases were not available.